Skip to main content

Kura Oncology, Inc.

KURA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001422143

In the last 90 days, Kura Oncology, Inc. insiders filed 2 open-market purchases and 8 sales; 221 institutions reported holding it in 13F filings for Q2 2026, worth $953.1M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Kura Oncology, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of KURA: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders1741179+6
Shares80.5M6.97M82.4M+8.84M (+12.0%)
Value$1.66B$143.4M$1.61B+$93.1M (+6.2%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (22)

Institutions that held Kura Oncology, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to KURA in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.7,155,417$139.8M0.00%
Siren, L.L.C.1,339,942$26.2M1.31%
Point72 Asset Management, L.P.189,103$3.70M0.01%
Qube Research & Technologies Ltd103,069$2.01M0.00%
Schroder Investment Management Group60,847$1.19M0.00%
ExodusPoint Capital Management, LP54,971$1.07M0.01%
Cubist Systematic Strategies, LLC45,927$897.4K0.01%
Balyasny Asset Management LLC33,797$660.4K0.00%
Dynamic Technology Lab Private Ltd30,508$596.0K0.06%
ADAR1 Capital Management, LLC30,000$586.2K0.10%
Intech Investment Management LLC15,257$298.1K0.00%
Point72 Asia (Singapore) Pte. Ltd.13,720$268.1K0.05%
Long Corridor Asset Management Ltd10,000$195.4K0.17%
Point72 (DIFC) Ltd7,483$146.2K0.01%
nVerses Capital, LLC1,300$25.4K0.01%
Jaffetilchin Investment Partners, LLC350$6.84K0.00%
Ashton Thomas Securities, LLC250$4.88K0.00%
Clear Street Markets LLC139$3.00K0.00%
Capital Performance Advisors LLP147$2.87K0.00%
True Wealth Design, LLC110$2.15K0.00%
Sterling Capital Management LLC75$1.47K0.00%
National Bank of Canada1$200.00%

Sold out (16)

Institutions that held Kura Oncology, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of KURA in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Artal Group S.A.1,819,884$37.5M
Ameriprise Financial Inc182,557$3.76M
Integral Health Asset Management, LLC100,000$2.06M
Superstring Capital Management LP36,242$746.2K
Marshall Wace, LLP26,267$540.8K
MYDA Advisors LLC20,000$411.8K
Prudential Financial Inc18,277$376.3K
Squarepoint Ops LLC16,319$336.0K
Capstone Investment Advisors, LLC13,517$278.3K
Principal Financial Group Inc12,492$257.2K
Engineers Gate Manager LP12,078$248.7K
Walleye Trading LLC747$15.4K
Pacer Advisors, Inc.709$14.6K
Innealta Capital, LLC54$1.11K
Main Street Group, LTD50$1.06K
Quantbot Technologies LP14$288

Not filed for Q3 2024 yet (1)

Institutions that held Kura Oncology, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding KURA in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.6,965,806$143.4M